Hikma Pharmaceuticals PLC Annual report 2010 notes to tHe ConsoLIdAted FInAnCIALstAtements Continued 14.
IntAnGIBLe Assets Continued other intangible assets Continued In process R&D In process R&D represents the pipeline of products under development that were recognised on the acquisition of Arab Pharmaceutical Manufacturing Company and Hikma Pharma SAEEgypt.
The In process R&D has an average estimated useful life of 15 years 2009: 15 years.
Trade name Trade names were recognised on the acquisition of Ribosepharm, Arab Pharmaceutical Manufacturing Company and Ibn Al Baytar.
The trade name recognised on the acquisition of Ribosepharm is expected to have an indefinite economic useful life due to its expected longevity.
The carrying value of Ribosepharms trade name is USD 5,550,000 2009: USD 6,003,000, the movement has arisen due to retranslation.
The trade name recognised on the acquisition of Arab Pharmaceutical Manufacturing Company has an estimated useful life of 12 years 2009:12years.
Software Software intangibles mainly represent the Enterprise Resource Planning solution that is being implemented in different operations across the Group.
The software has an average estimated useful life of five years.
Other acquisition related intangibles This mainly represents intangible assets recognised on the acquisition of Thymoorgan which relate to its specialist manufacturing capabilities.
The estimated useful lives vary from 10 years to indefinite useful life.
The carrying value of assets with indefinite lives is USD 994,000 2009: USD 1,075,000, the movement relates to retranslation at year end rates.
